Oncology & Cancer

Lymphoma cell metabolism may provide new cancer target

Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study ...

Medications

Axicabtagene ciloleucel slows large B-cell lymphoma

(HealthDay)—For patients with refractory or relapsed large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) leads to improvements in event-free survival and response compared with standard care, according to a study published ...

Medications

New hope for patients with relapsed large B-cell lymphoma

Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, ...

Oncology & Cancer

Thanks to clinical trials, big leaps made in lymphoma treatment

Newer therapies are outpacing the current treatment for diffuse large B cell lymphoma, according to data that scientists will deliver from two major clinical trials at the American Society of Hematology (ASH) annual meeting ...

Oncology & Cancer

Receptor structure reveals new targets for cancer treatment

A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule—its role in the ...

Oncology & Cancer

Using PET scans to better treat cancer patients

One of the primary tools that oncologists use to stage cancers is the PET (positron emission tomography) scan, an imaging test that uses a small amount of radioactive sugar to detect metabolically active areas within the ...

page 11 from 40